ENGLEWOOD, Colo., July 28, 2021 /PRNewswire/ -- Ampio
Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical
company focused on the advancement of immunology-based therapies
for prevalent inflammatory conditions, today announced details on
the Company's abstract presentation, "Significant Inhibition of the
TLR7/CXCL10 Signaling Axis by LMWF5A in Monocytic Lineages;
Implications for COVID-19 and Lupus Nephritis," being given
virtually at the 14th International Congress on Systemic Lupus
Erythematosus (LUPUS 2021) & 6th International Congress on
Controversies in Rheumatology and Autoimmunity (CORA) on
October 6-9, 2021.
Ampio's presentation is based on the Company's analysis that
Ampio's drug candidate, Ampion™, currently under clinical
investigation for the treatment of osteoarthritis and the
hyper-inflammation observed with severe COVID-19, inhibits
pro-inflammatory cytokine release, also known as the cytokine
storm.
The presentation will summarize evidence that treatment
utilizing Ampion suppresses Toll Like Receptor 7/8 (TLR7/8)
signaling in monocytic/macrophage lineages and suggests a role
for Ampion in treating the dysregulation of these pathways observed
in lupus nephritis as well as in COVID-19. Toll Like Receptors are
fundamental, innate mechanisms to detect and respond to pathogens
(pathogen-associated molecular patterns, PAMPs, including viruses
such as SARS-Cov2) or damaged cells (damage-associated molecular
patterns, DAMPs) by activating a proinflammatory cascade in immune
cells. Such dysregulated hyperactivation of these pathways is
associated with the cytokine/chemokine storm observed in severe
COVID-19 patients.
Ampio recently announced early positive data in its AP-014 Phase
I clinical trial, utilizing Ampion in treating respiratory distress
in patients as a result of COVID-19. The study showed inhaled
Ampion reduced all-cause mortality in COVID-19 respiratory distress
by 78% over the Standard of Care (SOC) alone.
For more information on the abstract presentation or LUPUS 2021
and CORA, visit https://lupus2021.kenes.com/.
About Ampio Pharmaceuticals
Ampio Pharmaceuticals, Inc. is a biopharmaceutical company
primarily focused on the advancement of immunology-based therapies
to treat prevalent inflammatory conditions for which there are
limited treatment options. Ampio's lead drug, Ampion™, is backed by
an extensive patent portfolio with intellectual property protection
extending through 2037 and will be eligible for 12-year FDA market
exclusivity upon approval as a novel biologic under the Biologics
Price Competition and Innovation Act (BPCIA).
Forward Looking Statements
Ampio's statements in this press release that are not historical
fact, and that relate to future plans or events, are
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by using words such as "believe,"
"expect," "plan," "anticipate," and similar expressions. These
forward-looking statements include statements regarding Ampio's
expectations with respect to Ampion and its classification, as well
as those associated with regulatory approvals and other FDA
decisions, the Biological License Application (BLA), the ability of
Ampio to enter into partnering arrangements, clinical
trials and decisions and changes in business conditions and similar
events, the ability to receive regulatory approval to conduct
clinical trials, that Ampion may be used to treat ARDS induced by
COVID-19, all of which are inherently subject to various risks and
uncertainties. The risks and uncertainties involved include those
detailed from time to time in Ampio's filings with the Securities
and Exchange Commission, including without limitation, under
Ampio's Annual Report on Form 10-K and other documents filed with
the Securities and Exchange Commission. Ampio undertakes no
obligation to revise or update these forward-looking statements,
whether as a result of new information, future events or
otherwise.
Media Contact
Katie Kennedy
katiek@gregoryfca.com
610-731-1045
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ampio-pharmaceuticals-to-present-at-the-14th-international-congress-on-systemic-lupus-erythematosus-lupus-2021--6th-international-congress-on-controversies-in-rheumatology-and-autoimmunity-cora-301343031.html
SOURCE Ampio Pharmaceuticals, Inc.